Elia Seguí, MD

New in @CCR_AACR: Neoadj. CT+IO improves pCR, EFS & OS in TNBC, but among those who relapse, most do so early (<24m)—especially in pts with residual disease (see below). Urgent need for trials in this high-risk group: ICI+ADC? ICI+VEGF? Bispecifics? 🔗 doi.org/10.1158/1078-0…

Dr. Marleen Kok (@lab_kok) delivered an excellent #HarvardBreastCancerCourse Schlager Lecture on #Immunotherapy in Early #BreastCancer. The Schlager lectureship brings in world leading cancer investigators working in women's cancers.

True pleasure to open the 3rd Annual ADC Toxicity Summit with a workshop dedicated to improving the safety of ADCs — co-chaired with awesome colleague @elia_segui. Incredible multidisciplinary discussions and great opportunity of prolific cross-talk between academia and industry!

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing…

So honored! Thanks to @CancerResearch for this recognition and amazing opportunity

Recent rationale in metastatic breast cancer for bringing ADCs into the 1st line has quoted very high 1st line attrition rates of patients not making it to second line. This study is likely more accurate of 2025 patients. In total, 9% of patients with MBC do not make it to…

Dream team breast cancer researchers @DFCI_BreastOnc @DanaFarber pioneering advancement therapeutics for patients #bcsm @ASCO @stolaney1 @AnnPartridgeMD @DrHBurstein @nlinmd @elmayermd @drsarahsam @FilipaLynce @adawaksmd @hthrparsons @IlanaSchlam @esalehiDNP @PTarantinoMD

Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. @ASCO #ASCO25 @OncoAlert

Late-breaking research at #ASCO25 in triple-negative breast cancer: @DanaFarber's @stolaney1 presents on phase 3 findings that show sacituzumab govitecan plus pembrolizumab could be a new first-line treatment option for PDL1+ patients with metastatic triple-negative…

@DFCI_BreastOnc is ready for a practice-changing Metastatic Breast Cancer Session at #ASCO25. Here we go!!!

Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment. #ASCO25